Evidence map›Paper›PMID 36456799›Full record

ArticleScientific reports2022

Apitherapy combination improvement of blood pressure, cardiovascular protection, and antioxidant and anti-inflammatory responses in dexamethasone model hypertensive rats.

Fatma El-Zahraa Abd El-Hakam, Gomaa Abo Laban, Sahar Badr El-Din, Hala Abd El-Hamid, Mohammed Hamdy Farouk

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Modulatory role ofFrontiers in pharmacology · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Fatma El-Zahraa Abd El-HakamPharmacology Department, Faculty of Medicine for Girls, Al-Azhar University, Nasr City, 11884, Cairo, Egypt. fatmaabdelhakem.medg@azahr.edu.eg.ORCID 0000-0001-9401-4996
Gomaa Abo LabanPlant Protection Department, Faculty of Agriculture, Al-Azhar University, Nasr City, 11884, Cairo, Egypt.
Sahar Badr El-DinPharmacology Department, Faculty of Medicine for Girls, Al-Azhar University, Nasr City, 11884, Cairo, Egypt.
Hala Abd El-HamidPathology Department, Faculty of Medicine for Girls, Al-Azhar University, Nasr City, 11884, Cairo, Egypt.
Mohammed Hamdy FaroukAnimal Production Department, Faculty of Agriculture, Al-Azhar University, Nasr City, 11884, Cairo, Egypt. mhfarouk@azhar.edu.eg.ORCID 0000-0001-5989-1782
Al-Azhar University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension-induced ventricular and vascular remodeling causes myocardial infarction, heart failure, and sudden death. Most available pharmaceutical products used to treat hypertension lead to adverse effects on human health. Limited data is available on apitherapy (bee products) combinations for treatment of hypertension. This study aims to evaluate the antihypertensive effects of combinations of natural apitherapy compounds used in the medical sector to treat a variety of diseases. Rats were assigned into six groups consisting of one control group and five hypertensive groups where hypertension (blood pressure > 140/90) was induced with dexamethasone. One of these groups was used as a hypertension model, while the remaining four hypertensive groups were treated with a propolis, royal jelly, and bee venom combination (PRV) at daily oral doses of 0.5, 1.0, and 2.0 mg/kg, and with losartan 10 mg/kg. The PRV combination at all doses decreased arterial blood pressure below the suboptimal value (p < 0.001), and PRV combination treatment improved dexamethasone-induced-ECG changes. The same treatment decreased angiotensin-II, endothelin-1, and tumor growth factor β serum levels in hypertensive rats. Additionally, PRV combination improved histopathological structure, and decreased serum levels of NF-kB and oxidative stress biomarkers. We concluded that PRV combination therapy may be used as a potential treatment for a variety of cardiovascular diseases.

Indexed as

HypertensionMyocardial InfarctionAnimalsAnti-Inflammatory AgentsAntioxidantsApitherapyBlood PressureDexamethasoneHeart VentriclesHumansRatsAnti-Inflammatory AgentsAntioxidantsDexamethasone

Identifiers

PMID36456799
PMCPMC9714403
OpenAlexW4311068036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.